布地奈德胶囊怎么使用的

Budesonide is approved for use in patients with glucocorticoid-dependent or -independent bronchial asthma and asthmatic chronic bronchitis. This product can be used for enema in patients with mild or moderate colonic Crohn's disease and ulcerative colitis limited to the sigmoid colon. How to use budesonide capsules?

Budesonide is taken once daily in the morning. Swallow whole. Do not chew or crush. For patients who are unable to swallow the entire capsule, open the capsule and pour the granules into a tablespoon of applesauce. Mix and consume entire contents within 30 minutes. Do not chew or crush. Follow with 8 ounces of water. Avoid grapefruit juice during treatment.

Budesonide for mildly to moderately active Crohn's disease: Adults: 9 mg daily for up to 8 weeks; repeat 8-week course of treatment with recurrent episodes of active disease. Pediatrics 8 to 17 years weighing more than 25 kg: 9 mg once daily for up to 8 weeks, then 6 mg once daily for 2 weeks.

Maintaining clinical remission in mild to moderate Crohn's disease. Adults: 6 mg daily for up to 3 months; stop after 3 months of completion of tapering. Continuation of treatment beyond 3 months has not been shown to provide substantial clinical benefit. When switching from oral prednisolone, begin tapering the prednisolone dose and simultaneously initiate ENTOCORT EC.

Budesonide was approved for import and marketing in my country in November 2001. It can induce the synthesis of lipocortin, inhibit phospholipase A2, and reduce the production and release of lipid inflammatory mediators such as platelet-activating factor, leukotrienes, and prostaglandins, which are produced by the hydrolysis of membrane phospholipids catalyzed by this enzyme. Induces the expression of angiotensin I converting enzyme and neutral endopeptidase, respectively accelerating the production of angiotensin II, and the degradation and inactivation of bradykinin and tachykinin; inhibits the expression of nitrous oxide synthase and reduces the production of nitrous oxide. Thereby constricting blood vessels, or reducing the effects of various other active substances other than vasotensin II on dilating blood vessels, causing inflammation, and inducing neurogenic inflammatory reactions. In addition, it can also induce the production of the vasoconstrictor substance angiocortin.